SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Event Requiring Report: June 9, 2004
SKINVISIBLE, INC.
(Exact name of registrant as specified in its charter)
NEVADA 000-25911 88-0344219
(State of Incorporation) (Commission (IRS Employer
File Number) Identification #)
6320 South Sandhill Road, Suite 10
Las Vegas, Nevada 89120
_______________________________
(Address of Principal Executive Offices)
(702) 433-7154
__________________________________________
(Registrant's telephone number, including area code)
_________________________________
(Registrant's Former Name and Address)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On June 9, 2004, our wholly-owned subsidiary, Skinvisible Pharmaceuticals, Inc. ("Skinvisible"), entered into a Trademark License Agreement and Distribution Agreement ("Distribution Agreement") with Cross Global, Inc. ("Cross Global"), a Delaware corporation, to grant Cross Global the exclusive right to distribute, market, sell, and promote Skinvisibles proprietary sunless tanning products in Canada, the United States, Mexico, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Luxembourg, Netherlands, Portugal, Spain, Sweden, United Kingdom, and Israel. These sunless spray tanning products incorporate Skinvisibles proprietary Invisicare® polymer delivery system for enhancing their adhesion to human skin.
The Distribution Agreement provides that Cross Global must pay Skinvisible an up-front royalty in the amount of $1,000,000. Cross Global paid $200,000 upon signing the Distribution Agreement and the remaining balance is to be made in payments in the amount of $200,000 on August 30, 2004, November 30, 2004, February 28, 2003, and May 30, 2005. Cross Global will also be responsible for payment of a running royalty in order to maintain the exclusivity granted under the Distribution Agreement. Under the terms of the Distribution Agreement, Cross Global is prohibited form manufacturing, marketing, distributing, or selling any competing product while the Distribution Agreement is in full force and effect.
The Trademark License Agreement and Distribution Agreement are attached as exhibits to this Current Report
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
EXHIBITS
Exhibit 10.1 Trademark License Agreement
Exhibit 10.2 Distribution Agreement
Exhibit 10.3 Amended Distribution Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SKINVISIBLE, INC.
By: Terry Howlett
Terry Howlett
Chief Executive Officer
Date: June 14, 2004